Leerink Partnrs Weighs in on KPTI Q1 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Karyopharm Therapeutics in a note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.39) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million.

Other equities research analysts have also recently issued reports about the company. Piper Sandler boosted their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Thursday. Finally, Royal Bank of Canada restated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Trading Down 1.9 %

KPTI stock opened at $0.60 on Friday. Karyopharm Therapeutics has a 12-month low of $0.53 and a 12-month high of $1.70. The stock has a market cap of $75.51 million, a price-to-earnings ratio of -0.59 and a beta of 0.06. The business’s 50-day moving average is $0.66 and its 200 day moving average is $0.76.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after buying an additional 43,856 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after buying an additional 792,283 shares during the last quarter. FMR LLC grew its holdings in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after buying an additional 76,510 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after buying an additional 543,556 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).